Platinum-induced nausea and vomiting in patients treated for head and neck cancer - 12/05/21
, François Cherifi 1, Zoé Neviere 1, Idlir Licaj 3, Bénédicte Clarisse 3, Florence Joly 1, 3Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 6 |
| Iconographies | 1 |
| Vidéos | 0 |
| Autres | 0 |
Summary |
Introduction |
Swallowing difficulties in patients with advanced head and neck cancer (HNC) represent an obstacle to adequate antiemetic prophylaxis before chemotherapy. We aim to assess chemotherapy-induced nausea and vomiting (CINV) risk in HNC patients in our center, with a specific focus among patients who could not receive appropriate NK1 receptor antagonist (NK1-RA) prophylaxis.
Materials and methods |
Prospective observational monocentric study. CINV were evaluated with the MASCC Antiemesis Tool self-questionnaire (MAT) for all patients treated by platinum-based chemotherapy for advanced HNC (January–April 2019), thereafter, only for patients without NK1-RA prophylaxis due to swallowing difficulties were included (May–October 2019).
Results |
Sixty-one patients were included (82% male, 49.2% reccurent/metastatic disease), 18 did not received NK1-RA prophylaxis due to swallowing difficulties. Among 52 patients included from January to April 2019, 17.3% reported swallowing difficulties. The chemotherapy regimen was highly and moderately emetic for 40 (65.6%) and 21 patients (34.4%), respectively. CINV was associated with both cisplatin-based chemotherapy (OR 10.66, 95% CI [2.17–52.08]) and exclusive chemotherapy (OR 7.76, 95% CI [1.79-33.78]). Patients who did not receive anti-NK1 prophylaxis had no more CINV than patients with adequate CINV prophylaxis.
Discussion |
CINV remains frequent in patients treated by platinum-based chemotherapy for HNC. Oral NK1-RA prophylaxis can be unavailable because of swallowing difficulties, without an increased risk of CINV.
Le texte complet de cet article est disponible en PDF.Keywords : Chemotherapy-induced nausea and vomiting, Antiemetic prophylaxis, NK1 receptor antagonists, Head and neck cancer, Deglutition disorders
Plan
Vol 108 - N° 5
P. 449-454 - mai 2021 Retour au numéro
Article précédent
- L’étude PROfound ou l’arrivée de la médecine personnalisée dans le cancer de la prostate
- Nadine Houédé
- Impact des facteurs nutritionnels pendant et après cancer
- Raphaëlle Ancellin, Vanessa Cottet, Laure Dossus, Philippine Fassier, Julie Gaillot de Saintignon, Julie Ginhac, Isabelle Romieu, Sébastien Salas, Stéphane Schneider, Bernard Srour, Marina Touillaud, Mathilde Touvier, Paule Latino-Martel
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?